Clinical trials: Residual
Neurobehavioral Manifestations, Drug Related Sleep Disturbance
Acute and Residual Effects of Caffeinated Beer
The aim of this study is to develop information about the acute and residual effects of a new product being targeted to young adults.
- Conditions
- Neurobehavioral Manifestations, Drug Related Sleep Disturbance, Alcohol Intoxication
- Trial name
- NCT00515294
- Testing
- Caffeinated Alcoholic Beer, Non-Caffeinated Alcoholic Beer, Caffeinated Non-Alcoholic Beer
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Boston University
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Refractive Errors
Early Feasibility Study to Evaluate the AccuraSee in Correcting Residual Refractive Errors After Cataract Surgery
To determine if the intraocular pseudophakic contact lens (IOPCL), referred to as the AccuraSee, corrects residual refractive errors after cataract surgery using a plus powered lens in subjects with ocular pathology previously…
- Trial name
- NCT05113979
- Testing
- AccuraSee IOPCL with +3.0D add
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- OnPoint Vision Inc
Chronic Lymphocytic Leukemia
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
The goal of this clinical research study is to learn if Revlimid (lenalidomide) can help to reduce the level of leukemia in your body. The safety of this drug will also be studied.
- Trial name
- NCT00632359
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
B Acute Lymphoblastic Leukemia, Minimal Residual Disease
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
This phase II trial studies how well pembrolizumab works in treating small amounts of cancer cells that remain after attempts to remove the cancer has been made in patients with acute lymphoblastic leukemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT02767934
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Neuromuscular Blockade
Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals
Aim: To explore the frequency of use of objective neuromuscular monitoring for assessment of depth of neuromuscular blockade in general anaesthesia the incidence of residual neuromuscular blockade, and the timing of reversal of…
- Trial name
- NCT02914119
- Testing
- Rocuronium, Succinylcholine, Cisatracurium
- Where
- Denmark
- Volunteers
- 30,430 people
- Sponsor
- Jakob Louis Thomsen
Respiratory Compliance, Functional Residual Capacity
Rescue Antenatal Steroids and Pulmonary Function Tests in Preterm Infants
One course of steroids given to a mother before a premature delivery helps the lungs of the premature infant and decreases breathing problems.
- Conditions
- Respiratory Compliance, Functional Residual Capacity, Pulmonary Function Testing
- Trial name
- NCT00669383
- Testing
- betamethasone
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Hairy Cell Leukemia
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Background: Hairy cell leukemia (HCL) is highly responsive to but not curable by cladribine (CdA). HCL responds to rituximab, which is not yet standard therapy for HCL.
- Trial name
- NCT00923013
- Testing
- Cladribine, Rituximab, BMbx
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
Hairy Cell Leukemia
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Background: Researchers are attempting to develop new treatments for hairy cell leukemia (HCL) that has not responded well to or has recurred after standard HCL therapies.
- Trial name
- NCT01059786
- Testing
- Pentostatin, Rituximab, Bendamustine
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Transplant; Complications, Postoperative Residual Curarization
Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery
The purpose of this study is to compare two medications that reverse muscle paralysis at the end of kidney transplant surgery with the goal of reducing residual muscle weakness and insufficient respiratory function after surgery.
- Conditions
- Kidney Transplant; Complications, Postoperative Residual Curarization, Postoperative Residual Weakness
- Trial name
- NCT03923556
- Testing
- Sugammadex, Neostigmine
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of Colorado, Denver
Atypical Choroid Plexus Papilloma, Choroid Plexus Carcinoma
Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery
This study will test the safety and efficacy of intra-arterial chemotherapy in subjects with newly diagnosed, residual, or recurrent atypical choroid plexus papilloma and choroid plexus carcinoma prior to a second surgery.
- Trial name
- NCT04994977
- Testing
- Melphalan, Carboplatin, Topotecan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Post-Amputation Pain, Phantom Limb Pain
Electrical Nerve Block for Amputation Pain
The purpose of the clinical trial is to learn whether electrical nerve block via the Altius System is a safe and effective treatment for patients with post-amputation pain.
- Conditions
- Post-Amputation Pain, Phantom Limb Pain, Residual Limb Pain, Stump Pain
- Trial name
- NCT02221934
- Testing
- Altius
- Where
- 22 sites in United States
- Volunteers
- 607 people
- Sponsor
- Neuros Medical, Inc.
Post-endoscopic Mucosal Resection of Colon Polyps
Assessing a Endoscopic Mucosal Resection Site Using Different Endoscopic Imaging Methods
The purpose of this study is to compare the accuracy of using different endoscopic imaging technique (white light, white light with near focus, narrow band imaging (NBI), NBI with near focus) for detection of residual neoplastic…
- Trial name
- NCT02668198
- Testing
- Olympus CF190 Colonoscope High definition white light, Olympus CF190 Colonoscope White light with near focus, Olympus CF190 Colonoscope Narrow band imaging
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Michael Wallace
Diabetic Kidney Disease
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease
- Trial name
- NCT01752985
- Testing
- BMS-813160
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 319 people
- Sponsor
- Bristol-Myers Squibb
Hemophilia A
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)
This Phase III clinical study will assess the impact of BMN 270 (compared to FVIII prophylaxis) on the number of bleeding episodes irrespective of exogenous FVIII replacement treatment in the efficacy evaluation period (EEP)…
- Trial name
- BMN 270-301 (NCT03370913)
- Testing
- valoctocogene roxaparvovec
- Where
- 49 sites in United States, Australia and 11 more
- Volunteers
- 144 people
- Sponsor
- BioMarin Pharmaceutical
Hemophilia A, Gene Therapy
Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5
This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, single dose study to determine the safety of valoctocogene roxaparvovec (an Adenovirus-Associated Virus (AAV) based gene therapy vector) in severe…
- Conditions
- Hemophilia A, Gene Therapy, Clotting Disorders, Blood Disorder
- Trial name
- GENEr8-AAV5+ (NCT03520712)
- Testing
- Valoctocogene Roxaparvovec
- Where
- 9 sites in South Africa, South Korea and 2 more
- Volunteers
- 3 people
- Sponsor
- BioMarin Pharmaceutical
Leukemia
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with chronic phase…
- Trial name
- NCT00428077
- Testing
- bcr-abl peptide vaccine, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Leukemia, Myeloid, Myelodysplastic Syndromes
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
The purpose of this study is to determine the maximum tolerated dose, dose limiting side effects, and the safety of increasing doses of lenalidomide in patients with AML and MDS who have a small amount of detectable disease after…
- Trial name
- UF-BMT-MRD-101 (NCT02370888)
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Florida
Multiple Myeloma
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance…
- Trial name
- AURIGA (NCT03901963)
- Testing
- Daratumumab, Lenalidomide
- Where
- 73 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Hemophilia A
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg
This Phase III clinical study will assess the efficacy of BMN 270 defined as FVIII activity, during weeks 49-52 following intravenous infusion of BMN 270 and assess the impact of BMN 270 on usage of exogenous FVIII replacement…
- Trial name
- GENEr8-2 (NCT03392974)
- Testing
- Valoctocogene Roxaparvovec
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- BioMarin Pharmaceutical